"The
Report HER2-Negative Breast Cancer - US Drug Forecast and Market
Analysis to 2023 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
Breast
cancer
is the second most common cancer in the world and the most common
cancer in women worldwide. This report focuses on the current
treatment landscape, unmet needs, current pipeline, and commercial
opportunities in the HER2-negative breast cancer market, with
coverage of multiple settings; neoadjuvant, adjuvant, first-,
second-, third-, and fourth-line metastatic.
Overall
five year survival in breast cancer is relatively high, at around
90%, but this is subjective to the subtype and stage of the disease.
Importantly this report segments HER2 negative breast cancer into its
two major subtypes; hormone receptor positive (HR+) and triple
negative breast cancer (TNBC).
The
US will remain the largest HER2-negative breast cancer market
throughout the forecast period. The growth of this market will be
driven by the high incidence of HER2-negative breast cancer in the
US, which almost equals that of the entire 5EU, combined with the
higher treatment rates in the neoadjuvant and adjuvant settings and
the influx of premium-priced products over the forecast period. In
particular, the prices for both the current and pipeline therapies
are the highest in the world, which is due to the private health
insurance system in the US, which can more easily afford to reimburse
the latest expensive drugs than the healthcare systems in other
countries.
Get
Sample copy of this Report @
http://www.marketresearchreports.biz/sample/sample/845847
Scope
-
Overview of HER2-Negative Breast Cancer including epidemiology,
etiology, symptoms, diagnosis, pathology and treatment guidelines as
well as an overview on the competitive landscape.
-
Detailed information on the key drugs in the US including product
HER2-Negative Breast Cancercription, safety and efficacy profiles as
well as a SWOT analysis.
-
Sales forecast for the top drugs in the US from 2013-2023.
-
Analysis of the impact of key events as well the drivers and
restraints affecting the US HER2-Negative Breast Cancer market.
Reasons
to buy
-
Understand and capitalize by identifying products that are most
likely to ensure a robust return
-
Stay ahead of the competition by understanding the changing
competitive landscape for HER2-Negative Breast Cancer.
-
Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth
analysis of drug performance
-
Obtain sales forecast for drugs from 2013-2023 in the US.
Read
our latest Press Release at
http://www.marketresearchreports.biz/pressreleases
Table
of Contents
1
Table of Contents 2
1.1
List of Tables 5
1.2
List of Figures 9
2
Introduction 11
2.1
Catalyst 11
2.2
Related Reports 11
2.3
Upcoming Related Reports 12
3
Disease Overview 13
3.1
Etiology and Pathophysiology 13
3.1.1
Etiology 13
3.1.2
Pathophysiology 14
3.1.3
Basic Breast Anatomy 15
3.2
Disease Classification/Staging Systems 16
3.3
Symptoms 18
3.4
Prognosis 18
3.5
Quality of Life 19
4
Disease Management 22
4.1
Diagnosis and Treatment Overview 22
4.1.1
Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 22
4.1.2
Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to
IIIC) 24
4.1.3
Treatment Guidelines and Leading Prescribed Drugs 28
4.2
US 29
4.2.1
Diagnosis 29
4.2.2
Clinical Practice 30
5
Competitive Assessment 33
5.1
Overview 33
5.2
Product Profiles (Branded Therapies) 34
5.2.1
Abraxane (nab-paclitaxel) 34
5.2.2
Afinitor (everolimus) 39
5.2.3
Avastin (bevacizumab) 43
5.2.4
Doxil/Caelyx (pegylated liposomal doxorubicin) 48
5.2.5
Halaven (eribulin mesylate) 53
5.2.6
Ixempra (ixabepilone) 56
5.2.7
Xeloda (capecitabine) 59
5.3
Product Profiles (Hormonal Agents) 62
5.3.1
Tamoxifen 62
5.3.2
Faslodex (fulvestrant) 62
5.3.3
Aromatase Inhibitors 63
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA:
Canada Toll Free: 866-997-4948
No comments:
Post a Comment